Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
61-75 of 298
Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
MinuteCE®Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
Giuseppe Curigliano, MD, PhD
Routes Reconsidered: A Case-Based Debate in SERD Selection
MinuteCE®Routes Reconsidered: A Case-Based Debate in SERD Selection
Giuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
Cynthia Villarreal-Garza, MD, DSc
The Future of Oral SERDs: Combination Strategies
MinuteCE®The Future of Oral SERDs: Combination Strategies
Komal Jhaveri, MD, FACP
Spotlight on Asia-Pacific: Practice Beyond Borders
MinuteCE®Spotlight on Asia-Pacific: Practice Beyond Borders
Hiraji Iwata, MD, PhD
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
MinuteCE®Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
Giuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
- advertisement
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
MinuteCE®Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
Komal Jhaveri, MD, FACP
Komal Jhaveri, MD, FACP
Giuseppe Curigliano, MD, PhD
Cynthia Villarreal-Garza, MD, DSc
Hiraji Iwata, MD, PhD
Safety of CDK4/6 Inhibitors: Anticipation, Prevention, and Management of Adverse Events
MinuteCE®Safety of CDK4/6 Inhibitors: Anticipation, Prevention, and Management of Adverse Events
Giuseppe Curigliano, MD, PhD
Giuseppe Curigliano, MD, PhD
Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
MinuteCE®Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
Komal Jhaveri, MD, FACP
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
MinuteCE®Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Kathleen Moore, MD, MS
- advertisement
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
MinuteCE®Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Joyce F. Liu, MD, MPH
Kathleen Moore, MD, MS
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
MinuteCE®Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Joyce F. Liu, MD, MPH
Kathleen Moore, MD, MS
